Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 13/20 | 0.46 |
| ▸ | JUN | P05412 | 6/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.46 |
| ▸ | RELA | Q04206 | 6/20 | 0.46 |
| ▸ | ATF1 | P18846 | 8/20 | 0.37 |
| ▸ | XPO1 | O14980 | 5/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469871 | 1.00 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL721758 | 0.83 | KEAP1 (0.47) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL29724129 | 0.81 | NFKB1 (0.45) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL1320432 | 0.81 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL8505560 | 0.81 | NFKB1 (0.45) | NFKB1JUNNFKB2RELAATF1 | |
| Hydrochloric Acid SCHEMBL7754141 | 0.81 | KEAP1 (0.46) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL914000 | 0.81 | NFKB1 (0.45) | NFKB1JUNNFKB2RELAATF1 | |
| Ethylene SCHEMBL29153723 | 0.79 | NFKB1 (0.44) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL10585289 | 0.79 | ALDH1A1 (0.38) | NFKB1JUNNFKB2RELAKEAP1 | |
| SCHEMBL3056707 | 0.79 | NFKB1 (0.55) | NFKB1JUNNFKB2RELAATF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452179-A | A kind of synthetic method of 2- chloro-4-methoxy -5- cyanopyrimidine | NANJING PURUIDA PHARMACEUTICAL TECH CO LTD | 2019-11-15 | — | — | CN | claimed |
| CN-103483323-B | Ai Wanafei | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2016-01-20 | — | — | CN | claimed |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025242880-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE | MY-T BIO LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025133338-A1 | QUINOLONE DERIVATVES AGAINST CANCER | GENOME THERAPEUTICS LTD (GB) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025125302-A1 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-4039523-A | YELLOW | CIBA-GEIGY AG (CH) | 1977-08-02 | — | — | US | disclosed |
| US-4024123-A | TEXTILES | DUSSY PAUL | 1977-05-17 | — | — | US | disclosed |
| US-4017477-A | 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs | CIBA-GEIGY AG (CH) | 1977-04-12 | — | — | US | disclosed |
| US-4001203-A | Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-4001205-A | WATER-SOLUBLE, FIBER-REACTIVE PHENYLAZODIHYDROXY, METHYL, CYANOPYRIDINE DYESTUFFS | CIBA-GEIGY AG (CH) | 1977-01-04 | — | — | US | disclosed |
| US-3989692-A | PHTHALOCYANINE DYES, WOOL, SILK, POLYAMIDES, CELLULOSE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
| US-3988310-A | FIBER-REACTIVE DYES; CELLULOSE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-10-26 | — | — | US | disclosed |
| US-3971738-A | Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component | CIBA-GEIGY AG (CH) | 1976-07-27 | — | — | US | disclosed |
| US-3956263-A | 4-Methyl-2,6-dihydroxy-3-cyanopyridine containing dyestuffs | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | SRC, CTTN, LCK | NFKB1 1407/4885JUN 2989/4885NFKB2 1285/4885 |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | NFKB1 2444/4885JUN 890/4885NFKB2 2923/4885 |
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | NFKB1 1372/4885JUN 1566/4885NFKB2 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.